BackModerna Overview

Moderna Total Liabilities

Moderna's total liabilities is $4.1B.

Get informed when a big investor buys or sells

+ Follow
Total Liabilities
$4.08B
↑ 54.66% YoYΔ $1.44B vs prior year quarter

Peer average

Loading

Moderna Total Liabilities History

Loading

Moderna vs. peers: Total Liabilities Comparison

Loading

Moderna Total Liabilities Growth (YoY per quarter)

Latest change versus the prior comparable period (same company).

Loading

Balance Sheet Breakdown

Current CashShort Term InvestmentsReceivablesInventoryOther Current AssetsCurrent AssetsLong Term InvestmentsProperty Plant EquipmentGoodwillIntangible AssetsOther AssetsTotal AssetsNet Tangible AssetsAccounts PayableOther Current LiabilitiesTotal Current LiabilitiesLong Term DebtOther LiabilitiesMinority InterestTotal Liabilities

Moderna (MRNA) FAQ

As of the most recent data (March 2026), MRNA shows a total liabilities of $4.1B. That compares with $2.6B in the prior-year period — up 54.7% year over year. Scroll down for historical charts and peer comparison views.

Compared with the year-ago period, MRNA's total liabilities is now $4.1B (was $2.6B) — a 54.7% year-over-year increase. Pairing that YoY change with peer averages gives a clearer picture of whether Moderna is outperforming or lagging.

Tracking MRNA's total liabilities over time shows whether Moderna is scaling, shrinking, or reshaping that part of the business. The current reading is $4.1B That compares with $2.6B in the prior-year period — up 54.7% year over year. Multi-quarter patterns matter more than any single print, which is why this page emphasizes history and peer comparison charts.

Besides this total liabilities page, Stockcircle has Moderna's full stock overview, other financial metrics, insider and congress trade tabs, and tools to follow the stock. Together they help you connect total liabilities (currently $4.1B) with ownership activity and broader fundamentals.

Moderna's total liabilities is $4.1B; compare it with other Healthcare names on the peer chart. Typical ranges vary by sub-industry, so always sanity-check against the closest competitors, not just the whole sector bucket.